Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Inspiring advances in research through scientific meetings

Manfred Windisch • 6 Mar 2024
AD/PD 2024
Alzheimer’s Disease Dementia

As Executive Organizer of AD/PD™, Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses the importance of the conference in inspiring advances for Alzheimer’s disease. He highlights the growth of the conference, and its aim to attract more young scientists and clinicians, with more than 40% of scientists in attendance below the age of 40. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Manfred Windisch

The direction of disease-modifying therapeutic development in Alzheimer’s disease
1:46
The direction of disease-modifying therapeutic development in Alzheimer’s disease
Manfred Windisch • 6 Mar 2024
The challenges of using animal models in Alzheimer’s research
1:36
The challenges of using animal models in Alzheimer’s research
Manfred Windisch • 6 Mar 2024
Updates in Alzheimer’s treatment: the potential of NSC001
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals